Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Reward Sensitivity and Pharmacotherapy for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT02162849
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
New Approaches to Smoking Cessation in Heavy Drinkers
- Conditions
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 26
- Registration Number
- NCT02151591
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients
- Conditions
- Interventions
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 7
- Registration Number
- NCT02147132
- Locations
- 🇺🇸
UC Physicians Company, LLC Opioid Treatment Program, Cincinnati, Ohio, United States
The MATCH (Medication Aids for Tobacco Cessation and Health) Study
- Conditions
- Interventions
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 968
- Registration Number
- NCT02146911
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Nicotine Dependence Clinic, Toronto, Ontario, Canada
My Mobile Advice Program: A Randomized Pilot Feasibility Study
- Conditions
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 66
- Registration Number
- NCT02136498
- Locations
- 🇺🇸
Group Health Research Institute, Seattle, Washington, United States
Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT02106637
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Effects of Varenicline on Plasticity in Schizophrenia
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 24
- Registration Number
- NCT01934023
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Improving Adherence to Smoking Cessation Medication Among PLWHA
- Conditions
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 158
- Registration Number
- NCT01898195
- Locations
- 🇺🇸
Spencer Cox Center for Health, New York, New York, United States
Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers
- Conditions
- Interventions
- Drug: Nicotine replacement therapy - Transdermal nicotine patchDrug: Nicotine replacement therapy - Nicotine gumDrug: Nicotine replacement therapy - Nicotine lozengeDrug: BupropionDrug: VareniclineDrug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gumDrug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozengeDrug: Combination pharmacotherapy - Transdermal nicotine patch + bupropionBehavioral: Tailored behavioral interventionBehavioral: Tobacco quitline referralBehavioral: Alcohol use risk reductionBehavioral: Behavioral activation for depressive symptomsBehavioral: Behavioral management of postcessation weight gain
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Mark Vander Weg
- Target Recruit Count
- 411
- Registration Number
- NCT01892813
- Locations
- 🇺🇸
Iowa City VA Healthcare System, Iowa City, Iowa, United States
Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 28
- Registration Number
- NCT01850953
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.